Sponsor Pipeline

Pharvaris Netherlands B.V. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
2
Recruiting
4
Phase 3
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-22 NCT05396105
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients…		 Trial sites reduced: 63 -> 60 locations
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-08-12 NCT07759141 EAP for Deucrictibant Immediate-release Available
Active Trials by Phase
Phase 3
3
Phase 2/3
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06679881 Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis… Hereditary Angioedema (HAE) Recruiting
NCT07266805 Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for… Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Recruiting
NCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema… Hereditary Angioedema (HAE) Active, Not Recruiting
Phase 2/3
NCT05396105 Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients… Hereditary Angioedema Enrolling by Invitation
Get alerts when Pharvaris Netherlands B.V.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free